ArticleEuropean journal of medical research2025
Upregulation of lncRNA CASC2 alleviates neuroinflammation in acute ischemic stroke and exhibits protective effects by targeting miR-155 (CASC2 role in AIS).
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Molecular Mechanism of LncRNA LUCAT1 Regulating HSPB8 Expression via miR-337-3p in Modulating Neurological Damage After Cerebral Infarction.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study investigated the effects of dysregulated lncRNA CASC2 (CASC2) and miR-155 on clinical prognosis and neuronal cell activity in patients with acute ischemic stroke (AIS), as well as identified potential biomarkers that mediate inflammation levels and prognostic outcomes in AIS.
methodsAIS cell models were established by inducing HT22 and BV-2 cells with OGD/R treatment. RT-qPCR quantified CASC2 and miR-155 expression. The levels of IL-1β, IL-6, IL-8 and TNF-α were detected by ELISA. Pearson correlation analysis was applied to assess the relationships between CASC2, miR-155 and NIHSS scores. ROC curve and binary Logistic analysis reflected the relevant indicators mediating the outcome of AIS patients. The targeting relationship between CASC2 and miR-155 was confirmed by DLR assay. The biological function of the cells was determined by CCK8 and FCM.
resultsCASC2 expression was significantly decreased in the serum of AIS patients, while miR-155 showed a positive trend, and this result was also reflected in the AIS patients with poor prognosis. CASC2 and miR-155 have reference value in predicting the prognosis of AIS patients. Functionally, CASC2 overexpression attenuated neuroinflammation and improved neuronal cell and microglia viability, whereas co-overexpression of miR-155 reversed these protective effects.
conclusionsCASC2 exerts a protective effect in AIS by sponging miR-155, thereby attenuating neuroinflammation and ameliorating clinical outcomes. CASC2 and miR-155 may serve as valuable prognostic biomarkers in AIS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.